NASDAQ:SESN Sesen Bio - SESN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sesen Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Add Compare Share Share Today's Range N/A50-Day Range$0.63▼$12.9952-Week Range N/AVolume1.87 million shsAverage Volume1.07 million shsMarket Capitalization$127.96 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Sesen Bio MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.04% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$842,886 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.09) to ($0.03) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.27 out of 5 starsMedical Sector979th out of 1,009 stocksPharmaceutical Preparations Industry478th out of 494 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Sesen Bio. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.04% of the outstanding shares of Sesen Bio have been sold short.Short Interest Ratio / Days to CoverSesen Bio has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sesen Bio has recently decreased by 31.17%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSesen Bio does not currently pay a dividend.Dividend GrowthSesen Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SESN. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Sesen Bio this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for SESN on MarketBeat in the last 30 days. This is a decrease of -85% compared to the previous 30 days.MarketBeat Follows4 people have added Sesen Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sesen Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $842,886.00 in company stock.Percentage Held by InsidersOnly 3.20% of the stock of Sesen Bio is held by insiders.Percentage Held by InstitutionsOnly 16.45% of the stock of Sesen Bio is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sesen Bio are expected to grow in the coming year, from ($0.09) to ($0.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sesen Bio is -6.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sesen Bio is -6.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Sesen Bio (NASDAQ:SESN) StockSesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA.Read More Receive SESN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sesen Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address SESN Stock News HeadlinesMarch 25, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Sesen Bio (NASDAQ:SESN)March 6, 2023 | bizjournals.comAfter revisions, Philadelphia-based Carisma Therapeutics poised to close merger with Sesen BioMarch 31, 2023 | The Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.March 2, 2023 | msn.comSesen Bio wins shareholder approval for Carisma mergerMarch 2, 2023 | finance.yahoo.comSesen Bio Stockholders Approve Merger with Carisma TherapeuticsFebruary 28, 2023 | finance.yahoo.comSesen Bio Reports Fourth Quarter and Full-Year 2022 Financial ResultsFebruary 24, 2023 | benzinga.comSHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and SHBI Shareholders About Its Ongoing InvestigationsFebruary 21, 2023 | finance.yahoo.comLeading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote "FOR" All Proposals to Approve Pending Merger With CarismaMarch 31, 2023 | WealthPop (Ad)Here’s Your Own Billion-Dollar Trading Edge (Just $0.76 a Week)2023 is a classic “stock picker’s market.” The only way to beat these markets is to pick the right stocks at the right time. Legendary trader Adam Mesh is ready to hand you his best stock pick every week… It’s the same kind of research Wall Street’s top traders use to beat the markets. Click here to get his three top picks for right now to help get you started now. February 16, 2023 | businesswire.comLeading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special MeetingFebruary 16, 2023 | finance.yahoo.comSesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending MergerFebruary 15, 2023 | finance.yahoo.com5 big dividend moves: Group 1 Automotive hikes by 20% | Pro RecapFebruary 15, 2023 | finance.yahoo.comBML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma TherapeuticsFebruary 14, 2023 | bizjournals.comSesen Bio, Carisma Therapeutics amend merger deal after reaching agreement with investor groupFebruary 14, 2023 | msn.comSesen gains 11% on amended terms for merger with CarismaFebruary 14, 2023 | finance.yahoo.comSesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending MergerFebruary 6, 2023 | finance.yahoo.comSesen Bio (NASDAQ:SESN) investors are sitting on a loss of 37% if they invested three years agoFebruary 2, 2023 | finance.yahoo.comSesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics MergerFebruary 2, 2023 | finance.yahoo.comThe Petri Dish: Departed White House adviser returns to the BroadJanuary 30, 2023 | finance.yahoo.comSesen Bio Receives NASDAQ Delisting NoticeJanuary 26, 2023 | finance.yahoo.comSesen Bio Reiterates Confidence that Pending Merger with Carisma is in Best Interests of StockholdersJanuary 19, 2023 | finance.yahoo.comSesen Bio Files Definitive Proxy Statement and Mails Letter to Stockholders in Connection with Pending Merger with Carisma TherapeuticsJanuary 6, 2023 | benzinga.comSHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and APEN Shareholders About Its Ongoing InvestigationsJanuary 5, 2023 | finance.yahoo.comInvestor Group Issues Letter to Sesen Bio’s Board of Directors Regarding Intent to Vote AGAINST Proposed Carisma MergerJanuary 4, 2023 | finance.yahoo.comSesen Bio Reiterates Confidence in Pending Merger with Carisma TherapeuticsJanuary 3, 2023 | msn.comSesen Bio investors reiterate plan to vote against Carisma mergerJanuary 3, 2023 | finance.yahoo.comCarisma Therapeutics and Sesen Bio merger draws opposition from large shareholderSee More Headlines Receive SESN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sesen Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address SESN Company Calendar Last Earnings11/07/2021Today3/31/2023Next Earnings (Estimated)5/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SESN CUSIPN/A CIK1485003 Webwww.sesenbio.com Phone(617) 444-8550Fax617-858-0911Employees35Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,880,000.00 Net MarginsN/A Pretax Margin-59.40% Return on Equity6.70% Return on Assets5.41% Debt Debt-to-Equity RatioN/A Current Ratio6.10 Quick Ratio6.10 Sales & Book Value Annual Sales$40 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow3.39 Book Value$0.78 per share Price / BookN/AMiscellaneous Outstanding Shares203,490,000Free Float196,980,000Market Cap$127.96 million OptionableOptionable Beta0.83 Key ExecutivesThomas R. CannellPresident, Chief Executive Officer & DirectorMonica ForbesChief Financial Officer & TreasurerStephanie VigueFinance DirectorJeannick CizeauHead of ResearchGlen C. MacDonaldChief Technology OfficerKey CompetitorsAraviveNASDAQ:ARAVShattuck LabsNASDAQ:STTKGossamer BioNASDAQ:GOSSProPhase LabsNASDAQ:PRPHLumiraDxNASDAQ:LMDXView All CompetitorsInsiders & InstitutionsThomas R CannellSold 24,374 sharesTotal: $287,613.20 ($11.80/share)Monica ForbesSold 17,292 sharesTotal: $204,045.60 ($11.80/share)Glen C MacdonaldSold 8,518 sharesTotal: $100,512.40 ($11.80/share)Mark SullivanSold 10,960 sharesTotal: $129,328.00 ($11.80/share)Elly RyuSold 864 sharesTotal: $10,195.20 ($11.80/share)View All Insider TransactionsView All Institutional Transactions SESN Stock - Frequently Asked Questions When is Sesen Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023. View our SESN earnings forecast. How were Sesen Bio's earnings last quarter? Sesen Bio, Inc. (NASDAQ:SESN) announced its earnings results on Sunday, November, 7th. The company reported $7.20 earnings per share for the quarter, beating analysts' consensus estimates of ($1.40) by $8.60. When did Sesen Bio's stock split? Shares of Sesen Bio reverse split on the morning of Wednesday, March 8th 2023. The 1-20 reverse split was announced on Wednesday, March 8th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, March 8th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Sesen Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sesen Bio investors own include Amarin (AMRN), XOMA (XOMA), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Verastem (VSTM), Sorrento Therapeutics (SRNE), Novavax (NVAX), Biocept (BIOC), Micron Technology (MU) and OPKO Health (OPK). What is Sesen Bio's stock symbol? Sesen Bio trades on the NASDAQ under the ticker symbol "SESN." Who are Sesen Bio's major shareholders? Sesen Bio's stock is owned by a variety of institutional and retail investors. Top institutional investors include BML Capital Management LLC (4.06%), Millennium Management LLC (0.51%), Renaissance Technologies LLC (0.50%), Group One Trading L.P. (0.00%), Susquehanna International Group LLP (0.00%) and Blodgett Wealth Advisors LLC (0.30%). Insiders that own company stock include Elly Ryu, Glen C Macdonald, Mark Sullivan, Monica Forbes and Thomas R Cannell. View institutional ownership trends. How do I buy shares of Sesen Bio? Shares of SESN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. How much money does Sesen Bio make? Sesen Bio (NASDAQ:SESN) has a market capitalization of $0.00 and generates $40 million in revenue each year. The company earns $-19,880,000.00 in net income (profit) each year or ($0.10) on an earnings per share basis. How can I contact Sesen Bio? Sesen Bio's mailing address is 245 FIRST STREET SUITE 1800, CAMBRIDGE MA, 02142. The official website for the company is www.sesenbio.com. The company can be reached via phone at (617) 444-8550, via email at ir@sesenbio.com, or via fax at 617-858-0911. This page (NASDAQ:SESN) was last updated on 3/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.